CClinicalTrials.gg
CompletedNCT03481374Updated Apr 17, 2018

Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus.

An interventional study of autonomic function testing in Diabetes Mellitus, Type 1, sponsored by Hasselt University. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Hasselt University · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
79
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

testing of autonomic function and relationship with exercise and Qol in diabetic patients and controls

Read the detailed description

Cardiovascular autonomic neuropathy is a common (sub)clinical symptom in persons with type 1 diabetes mellitus. Subjects in this non-commercial, monocentric, interventional study undergo autonomic function tests, a maximal ergospirometry and three questionnaires about the quality of life (EQ-5D-3L), the capacity to do physical activities (IPAQ) and the experience of possible symptoms of autonomic dysfunction in daily life (SCOPA-AUT). In this way the influence of type 1 diabetes mellitus on the quality of life, the exercise capacity and the autonomic function can be studied.

The primary aim of this study investigates the potential correlations between the severity of diabetic cardiovascular autonomic neuropathy (DCAN) and both the quality of life and the exercise capacity. As a secondary aim, the influences of gender, age, number of years since diagnosis of type 1 diabetes mellitus, VO2 max predicted, maximal heart rate during exercise, minimal heart rate in rest, maximal RER (Respiratory exchange ratio) and relevant interaction terms are studied.

In total 52 test subjects with type 1 diabetes mellitus and 27 matched control subjects are selected to participate in this study.

02

Conditions studied

  • Diabetes Mellitus, Type 1
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Type 1 diabetes mellitus (only for the group of subjects with diabetes mellitus)
  • At least two years with diagnosis of type 1 diabetes mellitus
  • Subject is in a stable condition
  • No hospitalization for any reason in the past three months
  • 18 years or older
  • Being capable of doing physical activities
  • Understand the study design and the informed consent
  • Sign the informed consent
  • No simultaneously participation to another study
  • Being capable of moving to the study center

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension, atrial fibrillation and other cardiovascular conditions
  • Severe lung disease
  • Muscle deficiency
  • Medication with influence on the autonomic nervous system:

    • Beta blockers
    • Alfa blockers
    • Antidepressants
    • Non-catecholamines
    • (anti) cholinergic medication
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Active comparator
    subjects with Type 1 Diabetes mellitus

    Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing

    Diagnostic Test: autonomic function testing

  • Placebo comparator
    Healthy controls

    healthy people without known disease undergo autonomic function testing

    Diagnostic Test: autonomic function testing

Interventions

  • Diagnostic testautonomic function testing

    autonomic function testing, ergospirometry, three questionnaires Other Names: * The autonomic function tests consist of five tests: * The Valsalva maneuver * The isometric handgrip test * The deep breathing test * The cold pressor test * A short head-up tilt test * A maximal ergospirometry * Three questionnaires: * EQ-5D-3L: quality of life * IPAQ: capacity to do physical activities

05

What researchers measure

Primary outcomes

  1. VO2 max

    peak oxygen consumption

    Time frame: day 1

06

Study locations

1 site
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03481374
Lead sponsor
Hasselt University
Collaborators
Jessa Hospital
Responsible party
prof. dr. Paul Dendale (prof. dr., Hasselt University) — Principal investigator
First posted
Mar 29, 2018
Start date
Jul 1, 2016
Primary completion
Mar 31, 2017
Completion
Mar 31, 2017
Last update
Apr 17, 2018

Study contacts

Renee De Busser, student
study chair · Hasselt University
Anika Nys, student
study chair · Hasselt University
Paul Dendale, prof. dr.
principal investigator · Jessa Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion